ANIP Q4 2022 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$94M+54.7% YoY

Gross Profit

$58M61.5% margin

Operating Income

$2M1.9% margin

Net Income

-$4M-4.5% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$8M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$760M

Total Liabilities

$422M

Stockholders' Equity

$339M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$94M	$61M	+54.7%
Gross Profit	$58M	$27M	+114.2%
Operating Income	$2M	-$24M	+107.7%
Net Income	-$4M	-$24M	+82.4%

Revenue Segments

Generics, Established Brands, and Other

$77M81%

Rare Disease

$18M19%

Geographic Segments

United States

$93M99%

Canada

$1M1%